Sienna Cancer Diagnostics names interim CEO
Sienna Cancer Diagnostics has appointed an interim replacement to outgoing CEO Dr Kerry Hegarty.
Former Immune System Therapeutics CEO Dr Cliff Holloway assumed the role on Monday.
Holloway is also currently the Australasian representative for healthcare and chemical investment banking company Ferghana Partners Group and a director of biotech investment fund Newstar Ventures.
Hegarty stepped down as CEO last month after 10 years in the role, as part of Sienna’s long-term strategic transformation plan.
Sienna Chairman Dr Geoff Cumming said the board decided to appoint an interim CEO as quickly as possible while searching for a permanent replacement. Holloway is a possible candidate for the permanent position.
“The appointment of Cliff as an interim CEO will ensure the company has immediate access to a leader with the right mix of skills to guide Sienna into its next phase, and provide continuity through to the appointment of a permanent CEO,” he said.
“Dr Holloway is a high-calibre and well-regarded business leader; his strategic and tactical experience leading biotechnology companies through critical phases of their growth will be invaluable to Sienna. The board and I are looking forward to working with Cliff.”
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
